Skip to main content

Mike Hunkapiller, Sue Siegel, Jonathan Rothberg, Bill Ericson, David Weitz, Jeff Samberg, Thomas Meyers, Maynard Olson, Katherine Flagg

Mike Hunkapiller and Sue Siegel recently joined the board of directors of RainDance Technologies (see feature in this issue).
Hunkapiller is a general partner at Alloy Ventures, which he joined in 2004 after 21 years at Applied Biosystems, where his last position was president and general manager. He holds a BS in chemistry from Oklahoma Baptist University and a PhD in chemical biology from Caltech. Hunkapiller is also on the board of Pacific Biosciences, which is developing a next-generation DNA sequencer and is backed by Alloy Ventures.
Siegel is a partner with Mohr Davidow Ventures, which participated in a $23.7 million round of financing RainDance raised earlier this year (see In Sequence 05-08-07). Prior to joining MDV, she was president and director of Affymetrix. Siegel is also a member of the board of directors of Pacific Biosciences, which is also backed by MDV.
RainDance’s other directors are Jonathan Rothberg, a company founder, who also founded 454 Life Sciences; Bill Ericson, who leads investments in life sciences and software for MDV; and David Weitz, a professor of applied physics and physics at Harvard University. Jeff Samberg, managing member of Acadia Woods Partners, a New York-based investment partnership, is a board observer.

Thomas Meyers has joined the new Boston Office of Cooley Godward Kronish, a law firm specializing in representing technology and life sciences companies. He was chair of the intellectual property department at Sullivan & Worcester’s Boston office and recently was general counsel of Helicos BioSciences.

Maynard Olson will receive the 2007 Gruber Prize for Genetics on Oct. 24 at the American Society of Human Genetics annual meeting in San Diego, California. He is a professor of Genome Sciences at the University of Washington. The prize consists of a gold medal and $500,000. Olson was a key player in the Human Genome Project.

Katherine Flagg has become vice president of sales for ForteBio, a developer of label-free systems for real-time detection and analysis of molecular interactions. She joined the company from Rapid Micro Biosystems, where she was vice president for business development. Previously, she represented automated DNA sequencing and synthesis products at Pharmacia Biotech, now GE Healthcare. Flagg holds a BS in nutrition from Douglass College at Rutgers University.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.